HSCA Applauds House Committee on Energy and Commerce for Commitment to Supporting Quality and Protecting Patients from Counterfeit Medical Products
Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with the House Committee on Energy and Commerce’s open mark-up session on the Safeguarding Therapeutics Act and twelve other bills:
“HSCA and its member group purchasing organizations (GPOs) applaud Representatives Engel, Guthrie, and all members of the House Committee on Energy and Commerce for helping to protect the healthcare supply chain by working to advance the Safeguarding Therapeutics Act. As the United States continues to address the spread of the coronavirus, strengthening the healthcare supply chain is more important than ever before. The Safeguarding Therapeutics Act enhances the U.S. Food and Drug Administration’s (FDA) authority to destroy counterfeit drugs and medical devices at American ports of entry, preventing such products from entering the supply chain and helping to ensure a safe and reliable supply of products.
Click here to read the full statement.
Comments of the Healthcare Supply Chain Association (HSCA) on FDA Request for Comments on Ensuring a Competitive Marketplace for Biosimilars
On behalf of the Healthcare Supply Chain Association (HSCA), we...
Comments of the Healthcare Supply Chain Association on USTR Request for Comments on Additional Tariff Exclusions for COVID-19 Response
Dear Ambassador Lighthizer: On behalf of the Healthcare Supply Chain...
Group Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
Dear Commissioner Hahn, The undersigned groups share the Food and Drug...